Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Chemotherapy in Squamous NSCLC
NCT04073537Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in squamous cell carcinoma of the lung (SCCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
anlotinib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT04073537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073537.